Erratum
for
Gerber et al., J Clin Oncol 24 (8) 1310-1318.
Journal of Clinical Oncology, Vol 24, No 13 (May 1), 2006: pp. 2133
© 2006 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2006.03.003
ERRATUM
The March 10, 2006, review article by Gerber, Grossman, and Streiff titled, "Management of Venous Thromboembolism in Patients With Primary and Metastatic Brain Tumors" (J Clin Oncol 24:1310-1318, 2006) contained errors.
In the Treatment of VTE section, under the Pharmacologic Approaches subheading, the second-to-last sentence of the last paragraph was given as, "Patients also have an increased chance of bleeding during the initial month of therapy (when internal normalized factor fluctuations are more common), and those with persistent internal normalized ratio variability remains at high risk," whereas it should have read, "Patients also have an increased chance of bleeding during the initial month of therapy (when international normalized ratio fluctuations are more common), and those with persistent international normalized ratio variability remains at high risk."
In the VTE Phophylaxis section, under the Pharmacologic Approaches subheading, the last sentence of the first paragraph listed the term "intermittent pneumatic compression devised," whereas it should have been "intermittent pneumatic compression devices."
In Figure 2, an erroneous arrow appeared under the text, "Acute/progressive VTE symptoms?" The corrected version is reprinted below in its entirety.
|
) Melanoma, renal cell carcinoma, choriocarcinoma, and thyroid cancers are considered relative contraindictions depending on clinical circumstances. (
) Acute bleeding appears hyperdense on computed tomography (CT) scan for approximately 10 days; in postoperative patients, blood in the surgical cavity is a common radiographic finding and does not preclude anticoagulation. IVC, inferior vena cava; IV, intravenous; LMWH, low molecular weight heparin.
